Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
Tvardi Therapeutics, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker TVRD, will host a webinar featuring Dr. Randy Longman to discuss the evolving treatment landscape of ulcerative colitis (UC) and new data on their investigational oral small molecule drug TTI-109 targeting STAT3. The Phase 1 healthy volunteer results s…